In the context of network pharmacology, five constituents of ZGCD—namely lysine, quercetin, gamma-aminobutyric acid, stigmasterol, and beta-sitosterol—are posited to exert anti-diabetic cardiomyopathy (anti-DCM) effects through interactions with the molecular targets ASS1, SERPINE1, CACNA2D1, AVP, APOB, ICAM1, EGFR, TNNC1, F2, F10, IGF1, TNNI2, CAV1, INSR, and INS. Here, ASS1 is linked to familial dilated cardiomyopathy.